Premium
Reply to: Association Between Alendronate and All‐Cause Mortality and Cardiovascular Mortality Among Hip Fracture: An Alternative Explanation
Author(s) -
Sing ChorWing,
Wong Angel YS,
Kiel Douglas P,
Cheung Elaine YN,
Lam Joanne KY,
Cheung Tommy T,
Chan Esther W,
Kung Annie WC,
Wong Ian CK,
Cheung ChingLung
Publication year - 2018
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.3568
Subject(s) - medicine , censoring (clinical trials) , hazard ratio , hip fracture , confidence interval , meta analysis , randomized controlled trial , population , osteoporosis , environmental health , pathology
To the Editor: We are thankful to Prof. Nguyen and Dr. Tran for their interest in our study and we appreciate the opportunity to respond to their comments. As Prof. Nguyen and Dr. Tran suggested that censoring patients at the time of switching medications might have inflated the effect size, we investigated this potential bias by excluding patients with switching of medications. Of the 3,081 alendronate-treated patients, 281 patients (9.1%) switched the therapy during the study period. After excluding these patients, we observed similar findings (Table), suggesting that bias due to treatment of censoring data should be minimal in our study.